NCT01255137 2013-06-27Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical CancerNational Institutes of Health Clinical Center (CC)Phase 2 Completed13 enrolled 9 charts